Company intelligence / Profile preview

Biophytis

Paris, Ile-de-France, Francebiophytis.com ↗

Ownership: Public · BPTS
Employees: ~22
Development stage: Phase 2

Overview

Currently conducting Phase 2 clinical study (SARA) for sarcopenia in the US and Europe, and Phase 2-3 clinical study (COVA) for COVID-19 in Europe, Brazil, and the US. Recently postponed publication of annual financial statements for 2024 due to a €2.6 million refinancing operation announced in March 2025.

Therapeutic areas: OphthalmologyRare DiseasesMetabolic DisordersInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

20-hydroxyecdysone

2 more assets in the full pipeline.

Request access →

Partnerships

AFM-Telethon (for development of BIO101 for DMD treatment)

Financials

Market cap: $2.6M
Total revenue: $0
Enterprise value: $10.1M

Beyond the preview

Go deeper on Biophytis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biophytis.

Explore the full profile